JPWO2020029156A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020029156A5 JPWO2020029156A5 JP2021506622A JP2021506622A JPWO2020029156A5 JP WO2020029156 A5 JPWO2020029156 A5 JP WO2020029156A5 JP 2021506622 A JP2021506622 A JP 2021506622A JP 2021506622 A JP2021506622 A JP 2021506622A JP WO2020029156 A5 JPWO2020029156 A5 JP WO2020029156A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- solid form
- item
- pharmaceutical composition
- tartrate salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 52
- 239000007787 solid Substances 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000000546 pharmaceutic aid Substances 0.000 claims description 16
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical class [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
- FEWJPZIEWOKRBE-JCYAYHJZSA-N (+)-tartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 10
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(E)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 claims description 10
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 9
- 239000000594 mannitol Substances 0.000 claims description 9
- 235000010355 mannitol Nutrition 0.000 claims description 9
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 6
- 239000001358 L(+)-tartaric acid Substances 0.000 claims description 6
- 235000011002 L(+)-tartaric acid Nutrition 0.000 claims description 6
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 claims description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 229960001681 Croscarmellose Sodium Drugs 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 5
- 229960001855 mannitol Drugs 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 5
- 206010025135 Lupus erythematosus Diseases 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 4
- -1 SMCC50 Chemical compound 0.000 claims description 4
- 238000010928 TGA analysis Methods 0.000 claims description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 4
- 235000011010 calcium phosphates Nutrition 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000012458 free base Substances 0.000 claims description 4
- 230000002062 proliferating Effects 0.000 claims description 4
- 238000002411 thermogravimetry Methods 0.000 claims description 4
- 229940043253 Butylated Hydroxyanisole Drugs 0.000 claims description 3
- 229940095259 Butylated Hydroxytoluene Drugs 0.000 claims description 3
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 3
- CZBZUDVBLSSABA-UHFFFAOYSA-N Butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulphate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 229940046009 Vitamin E Drugs 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 3
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M sodium bisulfite Chemical group [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 3
- 229940001607 sodium bisulfite Drugs 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 3
- 229940001482 sodium sulfite Drugs 0.000 claims description 3
- 235000010265 sodium sulphite Nutrition 0.000 claims description 3
- 229940001474 sodium thiosulfate Drugs 0.000 claims description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 150000003712 vitamin E derivatives Chemical class 0.000 claims description 3
- 206010003816 Autoimmune disease Diseases 0.000 claims description 2
- 229960003563 Calcium Carbonate Drugs 0.000 claims description 2
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 206010013774 Dry eye Diseases 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims description 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 2
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 229940069328 Povidone Drugs 0.000 claims description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims description 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 230000001684 chronic Effects 0.000 claims description 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 claims description 2
- 200000000018 inflammatory disease Diseases 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 201000004681 psoriasis Diseases 0.000 claims description 2
- 230000002829 reduced Effects 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 238000001757 thermogravimetry curve Methods 0.000 claims description 2
- 230000003078 antioxidant Effects 0.000 claims 2
- 241000048284 Potato virus P Species 0.000 claims 1
- 150000003892 tartrate salts Chemical class 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 230000000111 anti-oxidant Effects 0.000 description 3
- 239000002274 desiccant Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229940032147 Starch Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive Effects 0.000 description 2
- 229960001714 calcium phosphate Drugs 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940078456 CALCIUM STEARATE Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 229960005168 Croscarmellose Drugs 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- 229940057948 Magnesium stearate Drugs 0.000 description 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229960004274 Stearic acid Drugs 0.000 description 1
- 229960004793 Sucrose Drugs 0.000 description 1
- 229940033134 Talc Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008202 granule composition Substances 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
Description
より簡潔な記載を提供するために、本明細書中で与えられる量的な表現のいくつかは、用語「約」で修飾されていない。用語「約」が、明示的に使用されるか使用されないかに関係なく、本明細書中で与えられるすべての数量は、所与の実際の値を指すことが意図されていること、およびそのような所与の値についての実験および/または測定の条件に起因する均等および近似値を含む、当該分野の通常の技術に基づいて合理的に推測されるであろうそのような所与の値の近似値を含むことも意図されていることが理解される。例えば、XRPDにおけるピークが、「約」特定の値と記載されるとき、その値は、±0.2°の範囲を含む。請求項に示される材料の量は、その文脈で通常達成される精度に関連した合理的な変動を少なくとも許容する範囲を含むと理解され、別段特定されていない場合は、通常、特定の値の前後±10%の範囲を含むように解釈されるべきである。DSCに対する温度が特定されている場合は、±3℃の範囲を含むと理解するべきである。 To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term "about." All quantities given herein are intended to refer to the actual value given, regardless of whether the term "about" is used explicitly or not, and that Any given value that would reasonably be inferred based on the ordinary skill in the art, including equivalents and approximations resulting from conditions of experimentation and/or measurement for such given value It is understood that it is also intended to include approximations of . For example, when a peak in XRPD is described as "about" a particular value, that value includes a range of ±0.2°. Quantities of materials indicated in claims are understood to include ranges that at least allow for reasonable variation associated with the accuracy normally achieved in the context, and unless otherwise specified, are generally of the specified value. Should be interpreted to include a range of ±10% before and after. Where temperatures are specified for DSC, it should be understood to include a range of ±3°C.
14.25mg、50mg、75mg、100mg、150mg、200mg、250mg、300mgおよび400mgから選択される、遊離塩基の化合物Aの重量に相当する量で、実施形態1~9のいずれか1つに記載の化合物Aの固体形態を含む、投与単位。 14. according to any one of embodiments 1-9, in an amount equivalent to the weight of the free base of Compound A selected from 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg and 400 mg A dosage unit comprising a solid form of Compound A.
化合物A-TAの薬物生成物を、34.26mgの酒石酸塩(化合物A-TA)に相当する25mgの化合物A遊離塩基を含む経口投与用のカプセル剤として調製した。そのカプセル剤は、32.00mgのProsolv(登録商標)SMCC50(ケイ化微結晶性セルロース)、89.74mgのProsolv(登録商標)SMCC90(ケイ化微結晶性セルロース)、3.20mgのクロスカルメロースナトリウム(VIVASOL(登録商標))および0.80mgのフマル酸ステアリルナトリウム(PRUV(登録商標))も含む。1つのカプセル剤における内容物の総重量は、160mgである。淡青色の不透明キャップおよび白色の不透明本体を有するサイズ#2のHPMCカプセルシェルを使用した。その化合物A-TAカプセル剤を高密度ポリエチレン(HDPE)ボトル内に包装し、モレキュラーシーブを備えた低密度ポリエチレン(LDPE)キャップで蓋をした。 The drug product of Compound A-TA was prepared as capsules for oral administration containing 25 mg of Compound A free base equivalent to 34.26 mg of tartrate salt (Compound A-TA). The capsule contains 32.00 mg Prosolv® SMCC50 (silicified microcrystalline cellulose), 89.74 mg Prosolv® SMCC90 (silicified microcrystalline cellulose), 3.20 mg croscarmellose Also contains sodium (VIVASOL®) and 0.80 mg sodium stearyl fumarate (PRUV®). The total weight of contents in one capsule is 160 mg. A size #2 HPMC capsule shell with a pale blue opaque cap and white opaque body was used. The Compound A-TA capsules were packaged in high density polyethylene (HDPE) bottles and capped with low density polyethylene (LDPE) caps fitted with molecular sieves.
HDPEボトル(モレキュラーシーブ乾燥剤および脱酸素剤を含む)に包装する。
図12は、このプロセスのフローダイアグラムを提供している。
本発明は、例えば、以下の項目を提供する。
(項目1)
酒石酸塩である、化合物A
(項目2)
化合物AとL-(+)-酒石酸との1:1塩である、項目1に記載の固体形態。
(項目3)
化合物Aの前記L-(+)-酒石酸塩の水和物である、項目1または2に記載の固体形態。
(項目4)
二水和物である、項目3に記載の固体形態。
(項目5)
結晶性である、前述の項目のいずれか1項に記載の固体形態。
(項目6)
2θに換算して、約5.7°、約9.8°、約11.6°、約14.7°、約15.4°、約16.1°、約17.1°、約19.3°、約23.8°、約24.5°および約25.4°から選択される少なくとも2つのピークを含む粉末X線回折パターンを有する結晶形態である、前述の項目のいずれか1項に記載の固体形態。
(項目7)
前記粉末X線回折パターンが、少なくとも3つのピークまたは少なくとも4つのピークまたは少なくとも5つのピークまたは少なくとも6つのピークまたは少なくとも7つのピークまたは少なくとも8つのピークまたは少なくとも9つのピークまたは少なくとも10個のピークを含み、前記ピークは、2θに換算して、約5.7°、約9.8°、約11.6°、約14.7°、約15.4°、約16.1°、約17.1°、約19.3°、約23.8°、約24.5°、約25.4°から選択される、項目6に記載の固体形態。
(項目8)
約74℃に吸熱ピークを含む示差走査熱量測定(DSC)サーモグラムを有する、前述の項目のいずれか1項に記載の固体形態。
(項目9)
実質的に図7に示されているような熱重量分析(TGA)を有する、前述の項目のいずれか1項に記載の固体形態。
(項目10)
少なくとも1つの薬学的に許容され得る賦形剤と混合された、前述の項目のいずれか1項に記載の化合物Aの固体形態を含む、薬学的組成物。
(項目11)
少なくとも2つの薬学的に許容され得る賦形剤を含む、項目10に記載の薬学的組成物。(項目12)
充填剤、崩壊剤、滑剤、接着剤、滑沢剤および酸化防止剤、例えば、重亜硫酸ナトリウム、亜硫酸ナトリウム、チオ硫酸ナトリウム、ブチル化ヒドロキシトルエン(酸化防止剤-264)、ブチル化ヒドロキシアニソール、クエン酸およびビタミンEから選択される少なくとも1つの薬学的に許容され得る賦形剤を含む、項目10または11に記載の薬学的組成物。
(項目13)
微結晶性セルロース、クロスカルメロースナトリウム、マンニトール、ポリビニルピロリドン(PVP)およびフマル酸ステアリルナトリウムからなる群より選択される少なくとも1つの薬学的に許容され得る賦形剤を含む、項目12に記載の薬学的組成物。
(項目14)
25mg、50mg、75mg、100mg、150mg、200mg、250mg、300mgおよび400mgから選択される、遊離塩基の化合物Aの重量に相当する量で、項目1~9のいずれか1項に記載の化合物Aの固体形態を含む、投与単位。
(項目15)
錠剤またはカプセル剤である、項目14に記載の投与単位。
(項目16)
化合物A-TAおよび1つまたはそれより多くの薬学的に許容され得る賦形剤を含む、項目14または項目15に記載の投与単位。
(項目17)
前記1つまたはそれより多くの薬学的に許容され得る賦形剤が、微結晶性セルロース、クロスカルメロースナトリウム、マンニトール、ポリビニルピロリドン(PVP)およびフマル酸ステアリルナトリウムからなる群より選択される1つまたはそれより多くの賦形剤を含む、項目16に記載の投与単位。
(項目18)
ケイ化微結晶性セルロース50、ケイ化微結晶性セルロース90、アルファ化デンプン、マンニトール、クロスカルメロースナトリウム、ポビドンおよびフマル酸ステアリルナトリウムから選択される少なくとも1つの薬学的に許容され得る賦形剤を含む、項目14~17のいずれかに記載の投与単位。
(項目19)
酸化防止剤、例えば、重亜硫酸ナトリウム、亜硫酸ナトリウム、チオ硫酸ナトリウム、ブチル化ヒドロキシトルエン(酸化防止剤-264)、ブチル化ヒドロキシアニソール、クエン酸およびビタミンEを含む、項目14~18のいずれか1項に記載の投与単位。
(項目20)
化合物Aを含む薬学的組成物と保護剤とを2つの別個の材料として閉鎖容器内に含む、包装された医薬品。
(項目21)
前記薬学的組成物が、項目14~18のいずれかに記載の投与単位を含む、項目19に記載の包装された医薬品。
(項目22)
前記保護剤が、乾燥剤、酸化防止剤、脱酸素物質および不活性ガスから選択される少なくとも1つの材料を含む、項目19~20のいずれか1項に記載の包装された医薬品。
(項目23)
前記保護剤が、モレキュラーシーブ、シリカゲルおよび繊維乾燥剤から選択される少なくとも1つの材料を含む、項目19~21のいずれか1項に記載の包装された医薬品。
(項目24)
前記保護剤および前記薬学的組成物が、気密容器内に入れられている、項目19~21のいずれか1項に記載の包装された医薬品。
(項目25)
前記気密容器が、密閉ボトルである、項目24に記載の包装された医薬品。
(項目26)
化合物Aの前記L-(+)-酒石酸塩を少なくとも1つの薬学的に許容され得る賦形剤と合わせる工程を含む、項目10~13のいずれか1項に記載の薬学的組成物を調製する方法。
(項目27)
前記少なくとも1つの薬学的に許容され得る賦形剤が、充填剤を含み、前記充填剤は、必要に応じて、マンニトール、デンプン、微結晶性セルロース(SMCC50、SMCC90を含む)、ラクトース、ゼラチン、アルファ化デンプン、スクロース、リン酸カルシウム、マルトデキストリン、ソルビトール、炭酸カルシウムおよびリン酸カルシウムから選択される、項目26に記載の方法。
(項目28)
前記少なくとも1つの薬学的に許容され得る賦形剤が、崩壊剤を含み、前記崩壊剤は、必要に応じて、クロスカルメロースナトリウム、カルボキシメチルスターチナトリウム、架橋ポリビニルピロリドンおよびデンプングリコール酸ナトリウムを含む、項目26または27に記載の方法。
(項目29)
前記少なくとも1つの薬学的に許容され得る賦形剤が、接着剤を含み、前記接着剤は、必要に応じて、ポリビニルピロリドン(PVP)、架橋PVP、ヒドロキシプロピルメチルセルロース(HPMC)、ヒドロキシプロピルセルロースまたはカルボキシメチルセルロースナトリウム(CMC-Na)である、項目26~28のいずれか1項に記載の方法。(項目30)
前記少なくとも1つの薬学的に許容され得る賦形剤が、滑沢剤を含み、前記滑沢剤は、必要に応じて、フマル酸ステアリルナトリウム、ステアリン酸マグネシウム、ステアリン酸カルシウム、コロイド状二酸化ケイ素、タルク、ステアリン酸、モノステアリン酸グリセリル、ミリスチン酸イソプロピルから選択される、項目26~29のいずれか1項に記載の方法。
(項目31)
化合物Aの前記L-(+)-酒石酸塩を、微結晶性セルロース、フマル酸ステアリルナトリウムおよびPVP、ならびに必要に応じてマンニトールと合わせて、混合物を形成する工程を含む、項目26に記載の方法。
(項目32)
化合物Aの前記L-(+)-酒石酸塩を、微結晶性セルロース、フマル酸ステアリルナトリウムおよびPVP、ならびに必要に応じてマンニトールと合わせて、混合物を形成する工程、ならびにPVPおよび必要に応じて水を加えて、湿顆粒混合物を形成する工程を含む、項目31に記載の方法。
(項目33)
項目26に記載の方法によって調製される、化合物A-TAを含む薬学的組成物。
(項目34)
前記混合物が、湿式造粒機においてブレンドされる、項目31または項目32に記載の方法。
(項目35)
化合物Aの前記L-(+)-酒石酸塩を調製するためのプロセスであって、溶媒の存在下において化合物AをL-(+)-酒石酸と接触させる工程を含む、プロセス。
(項目36)
化合物Aの固体形態を調製するためのプロセスであって、溶媒中で化合物Aを酒石酸と接触させる工程を含む、プロセス。
(項目37)
化合物Aの前記L-(+)-酒石酸塩が溶媒から固体として沈殿する条件下にて前記溶媒の存在下で化合物AをL-(+)-酒石酸と接触させる工程を含む、項目36に記載のプロセス。
(項目38)
前記溶媒が、水および有機共溶媒を含む、項目37に記載のプロセス。
(項目39)
前記有機共溶媒が、アセトン、イソプロパノール、エタノールおよびテトラヒドロフランから選択される、項目38に記載のプロセス。
(項目40)
化合物Aの前記固体形態が、化合物Aの前記L-(+)-酒石酸塩の形態Iを含む、項目39に記載のプロセス。
(項目41)
化合物Aまたはその薬学的に許容され得る塩を合成するプロセスであって、化合物2を得るための化合物1の還元的水素化
(項目42)
化合物2を化合物3と反応させて、化合物Aを得る工程:
(項目43)
化合物AをL-(+)-酒石酸と接触させて、化合物Aの前記L-(+)-酒石酸塩を得る工程をさらに含む、項目42に記載の方法。
(項目44)
被験体における増殖障害、増殖性障害、腫瘍、炎症性疾患、自己免疫疾患、乾癬、ドライアイ、関節リウマチまたは狼瘡から選択される状態を処置する方法であって、前記方法は、それを必要とする被験体に、項目1~9のいずれか1項に記載の化合物Aの固体形態またはその薬学的組成物を投与する工程を含む、方法。
(項目45)
前記状態が、慢性狼瘡、関節リウマチ、慢性リンパ性白血病および慢性骨髄性白血病から選択される、項目44に記載の方法。
Package in HDPE bottles (containing molecular sieve desiccant and oxygen scavenger).
Figure 12 provides a flow diagram of this process.
The present invention provides, for example, the following items.
(Item 1)
Compound A, which is the tartrate salt
(Item 2)
The solid form of item 1, which is a 1:1 salt of compound A and L-(+)-tartaric acid.
(Item 3)
3. The solid form of item 1 or 2, which is a hydrate of said L-(+)-tartrate salt of Compound A.
(Item 4)
4. A solid form according to item 3, which is the dihydrate.
(Item 5)
A solid form according to any one of the preceding items, which is crystalline.
(Item 6)
About 5.7°, about 9.8°, about 11.6°, about 14.7°, about 15.4°, about 16.1°, about 17.1°, about 19 in terms of 2θ Any one of the preceding items, in a crystalline form having an X-ray powder diffraction pattern comprising at least two peaks selected from .3°, about 23.8°, about 24.5° and about 25.4°. A solid form as described in Section 1.
(Item 7)
said powder X-ray diffraction pattern comprises at least 3 peaks or at least 4 peaks or at least 5 peaks or at least 6 peaks or at least 7 peaks or at least 8 peaks or at least 9 peaks or at least 10 peaks , the peaks are about 5.7°, about 9.8°, about 11.6°, about 14.7°, about 15.4°, about 16.1°, about 17° in terms of 2θ. 7. The solid form of item 6, selected from 1[deg.], about 19.3[deg.], about 23.8[deg.], about 24.5[deg.], about 25.4[deg.].
(Item 8)
The solid form of any one of the preceding items, having a differential scanning calorimetry (DSC) thermogram including an endothermic peak at about 74°C.
(Item 9)
7. A solid form according to any one of the preceding items having a thermogravimetric analysis (TGA) substantially as shown in FIG.
(Item 10)
A pharmaceutical composition comprising a solid form of Compound A according to any one of the preceding items admixed with at least one pharmaceutically acceptable excipient.
(Item 11)
11. A pharmaceutical composition according to item 10, comprising at least two pharmaceutically acceptable excipients. (Item 12)
Fillers, disintegrants, lubricants, adhesives, lubricants and antioxidants such as sodium bisulfite, sodium sulfite, sodium thiosulfate, butylated hydroxytoluene (antioxidant-264), butylated hydroxyanisole, citric 12. A pharmaceutical composition according to items 10 or 11, comprising at least one pharmaceutically acceptable excipient selected from acids and vitamin E.
(Item 13)
13. The pharmaceutical of item 12, comprising at least one pharmaceutically acceptable excipient selected from the group consisting of microcrystalline cellulose, croscarmellose sodium, mannitol, polyvinylpyrrolidone (PVP) and sodium stearyl fumarate. composition.
(Item 14)
Compound A according to any one of items 1 to 9 in an amount corresponding to the weight of the free base of Compound A selected from 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg and 400 mg. Dosage units containing solid forms.
(Item 15)
A dosage unit according to item 14, which is a tablet or capsule.
(Item 16)
A dosage unit according to item 14 or item 15 comprising Compound A-TA and one or more pharmaceutically acceptable excipients.
(Item 17)
wherein said one or more pharmaceutically acceptable excipients is one selected from the group consisting of microcrystalline cellulose, croscarmellose sodium, mannitol, polyvinylpyrrolidone (PVP) and sodium stearyl fumarate; 17. Dosage unit according to item 16, containing or more excipients.
(Item 18)
at least one pharmaceutically acceptable excipient selected from silicified microcrystalline cellulose 50, silicified microcrystalline cellulose 90, pregelatinized starch, mannitol, croscarmellose sodium, povidone and sodium stearyl fumarate A dosage unit according to any of items 14-17, comprising:
(Item 19)
Any one of items 14-18, including antioxidants such as sodium bisulfite, sodium sulfite, sodium thiosulfate, butylated hydroxytoluene (antioxidant-264), butylated hydroxyanisole, citric acid and vitamin E Dosage unit as described above.
(Item 20)
A packaged pharmaceutical product comprising a pharmaceutical composition comprising Compound A and a protectant as two separate materials in a closed container.
(Item 21)
Packaged pharmaceutical product according to item 19, wherein said pharmaceutical composition comprises a dosage unit according to any of items 14-18.
(Item 22)
21. Packaged pharmaceutical product according to any one of items 19-20, wherein the protective agent comprises at least one material selected from desiccants, antioxidants, oxygen scavengers and inert gases.
(Item 23)
22. Packaged pharmaceutical product according to any one of items 19-21, wherein said protective agent comprises at least one material selected from molecular sieves, silica gel and fiber desiccants.
(Item 24)
22. The packaged pharmaceutical product of any one of items 19-21, wherein said protective agent and said pharmaceutical composition are contained within an airtight container.
(Item 25)
25. The packaged pharmaceutical product of item 24, wherein said airtight container is a sealed bottle.
(Item 26)
Preparing a pharmaceutical composition according to any one of items 10 to 13, comprising combining said L-(+)-tartrate salt of Compound A with at least one pharmaceutically acceptable excipient Method.
(Item 27)
The at least one pharmaceutically acceptable excipient comprises fillers, which optionally include mannitol, starch, microcrystalline cellulose (including SMCC50, SMCC90), lactose, gelatin, 27. Method according to item 26, selected from pregelatinized starch, sucrose, calcium phosphate, maltodextrin, sorbitol, calcium carbonate and calcium phosphate.
(Item 28)
The at least one pharmaceutically acceptable excipient comprises a disintegrant, optionally comprising croscarmellose sodium, carboxymethyl starch sodium, cross-linked polyvinylpyrrolidone and sodium starch glycolate. , item 26 or 27.
(Item 29)
The at least one pharmaceutically acceptable excipient comprises an adhesive, optionally polyvinylpyrrolidone (PVP), crosslinked PVP, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose or 29. The method of any one of items 26-28, which is sodium carboxymethylcellulose (CMC-Na). (Item 30)
The at least one pharmaceutically acceptable excipient comprises a lubricant, optionally sodium stearyl fumarate, magnesium stearate, calcium stearate, colloidal silicon dioxide, talc , stearic acid, glyceryl monostearate, isopropyl myristate.
(Item 31)
27. The method of item 26, comprising combining said L-(+)-tartrate salt of Compound A with microcrystalline cellulose, sodium stearyl fumarate and PVP, and optionally mannitol to form a mixture. .
(Item 32)
combining said L-(+)-tartrate salt of Compound A with microcrystalline cellulose, sodium stearyl fumarate and PVP, and optionally mannitol to form a mixture, and PVP and optionally water to form a wet granule mixture.
(Item 33)
A pharmaceutical composition comprising compound A-TA prepared by the method of item 26.
(Item 34)
33. The method of item 31 or item 32, wherein the mixture is blended in a wet granulator.
(Item 35)
A process for preparing said L-(+)-tartaric acid salt of Compound A, comprising contacting Compound A with L-(+)-tartaric acid in the presence of a solvent.
(Item 36)
A process for preparing a solid form of Compound A, the process comprising contacting Compound A with tartaric acid in a solvent.
(Item 37)
37. The method of claim 36, comprising contacting Compound A with L-(+)-tartaric acid in the presence of said solvent under conditions such that said L-(+)-tartaric acid salt of Compound A precipitates as a solid from said solvent. process.
(Item 38)
38. The process of item 37, wherein the solvent comprises water and an organic co-solvent.
(Item 39)
39. The process of item 38, wherein said organic co-solvent is selected from acetone, isopropanol, ethanol and tetrahydrofuran.
(Item 40)
40. The process of item 39, wherein said solid form of Compound A comprises Form I of said L-(+)-tartrate salt of Compound A.
(Item 41)
A process for synthesizing compound A or a pharmaceutically acceptable salt thereof comprising reductive hydrogenation of compound 1 to give compound 2
(Item 42)
reacting compound 2 with compound 3 to obtain compound A:
(Item 43)
43. The method of item 42, further comprising contacting Compound A with L-(+)-tartaric acid to obtain said L-(+)-tartrate salt of Compound A.
(Item 44)
A method of treating a condition selected from a proliferative disorder, a proliferative disorder, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye, rheumatoid arthritis or lupus in a subject, said method requiring administering a solid form of Compound A according to any one of items 1 to 9 or a pharmaceutical composition thereof to a subject.
(Item 45)
45. The method of item 44, wherein said condition is selected from chronic lupus, rheumatoid arthritis, chronic lymphocytic leukemia and chronic myelogenous leukemia.
Claims (22)
をさらに含む、請求項17に記載のプロセス。18. The process of claim 17, further comprising:
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021116171A JP2021165316A (en) | 2018-08-09 | 2021-07-14 | Process for producing (s)-n-(3-((2-((4-((1-acetylpyrrolidine-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidine-4-yl)oxy)phenyl)acrylamide and formulations thereof |
JP2023150120A JP2023161038A (en) | 2018-08-09 | 2023-09-15 | Process for producing (s)-n-(3-((2-((4-((1-acetylpyrrolidine-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidine-4-yl)oxy)phenyl)acrylamide and formulations thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2018/099535 WO2020029156A1 (en) | 2018-08-09 | 2018-08-09 | Process for manufacture of (s)-n-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy) phenyl)acrylamide, and formulations thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021116171A Division JP2021165316A (en) | 2018-08-09 | 2021-07-14 | Process for producing (s)-n-(3-((2-((4-((1-acetylpyrrolidine-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidine-4-yl)oxy)phenyl)acrylamide and formulations thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022501317A JP2022501317A (en) | 2022-01-06 |
JPWO2020029156A5 true JPWO2020029156A5 (en) | 2022-09-30 |
Family
ID=69413664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021506622A Pending JP2022501317A (en) | 2018-08-09 | 2018-08-09 | (S) -N- (3-((2-((4-((1-Acetylpyrrolidine-3-yl) (methyl) amino) phenyl) amino) -5-methoxypyrimidine-4-yl) oxy) phenyl ) Process for the production of acrylamide and its formulation |
Country Status (7)
Country | Link |
---|---|
US (1) | US20210309642A1 (en) |
EP (1) | EP3833659A4 (en) |
JP (1) | JP2022501317A (en) |
CN (1) | CN112752750A (en) |
AU (1) | AU2018436086B2 (en) |
CA (1) | CA3109085A1 (en) |
WO (1) | WO2020029156A1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9464089B2 (en) * | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
EP2802568A1 (en) * | 2012-01-13 | 2014-11-19 | Acea Biosciences, Inc. | Heterocyclic compounds and uses as anticancer agents. |
JP6564771B2 (en) * | 2013-07-11 | 2019-08-21 | エイシア バイオサイエンシーズ インコーポレイテッド | Pyrimidine derivatives as kinase inhibitors |
-
2018
- 2018-08-09 AU AU2018436086A patent/AU2018436086B2/en active Active
- 2018-08-09 US US17/266,075 patent/US20210309642A1/en active Pending
- 2018-08-09 EP EP18929249.3A patent/EP3833659A4/en active Pending
- 2018-08-09 JP JP2021506622A patent/JP2022501317A/en active Pending
- 2018-08-09 WO PCT/CN2018/099535 patent/WO2020029156A1/en unknown
- 2018-08-09 CA CA3109085A patent/CA3109085A1/en active Pending
- 2018-08-09 CN CN201880098022.2A patent/CN112752750A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11007152B2 (en) | Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant | |
US7855233B2 (en) | Citrate salt of Rasagiline | |
EP2902384B1 (en) | Form of ivabradine hydrochloride | |
US20100010098A1 (en) | Polymorphs of rasagiline hydrochloride | |
US20140357860A1 (en) | Salt of ivabradine with adipic acid | |
RU2687282C2 (en) | Stable combined pharmaceutical composition | |
EP2691083A1 (en) | Pharmaceutical composition of sitagliptin | |
JP6168673B2 (en) | Arylalkylamine compound-containing pharmaceutical composition | |
KR20230175186A (en) | Psilocybin compositions, methods of making and using the same | |
US7186863B2 (en) | Sertraline compositions | |
KR102447769B1 (en) | The crystalline form of valbenazine tosylate and its preparation and use | |
JP2023501757A (en) | Prarcetinib pharmaceutical composition | |
US8124640B2 (en) | Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof | |
RU2193560C2 (en) | Novel salt | |
JPWO2020029156A5 (en) | ||
US10583087B2 (en) | Pharmaceutical composition for oral administration | |
WO2022095913A1 (en) | Solid formulation | |
US9714225B2 (en) | Processes for the preparation of lorcaserin | |
TWI835834B (en) | Process for manufacture of (s)-n-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy)phenyl)acrylamide, and formulations thereof | |
TW202012397A (en) | Process for manufacture of (s)-n-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy)phenyl)acrylamide, and formulations thereof | |
JP2023161038A (en) | Process for producing (s)-n-(3-((2-((4-((1-acetylpyrrolidine-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidine-4-yl)oxy)phenyl)acrylamide and formulations thereof | |
CN114272239A (en) | Package of edaravone solid dispersion or preparation thereof | |
US20240122857A1 (en) | Pharmaceutical formulations of indoleamine 2, 3-dioxygenase inhibitors | |
JP2015193611A (en) | stable solid pharmaceutical composition | |
EA045037B1 (en) | PHARMACEUTICAL COMPOSITIONS OF INDOLAINE-2,3-DIOXYGENASE INHIBITORS |